Pete Conway, Executive Advisor (Industry)
Pete Conway has 20 years’ experience as both a Health Economist and Market Access Lead in the pharmaceutical industry, working across many therapeutic areas. Initially trained as a hospital/clinical pharmacist in the UK, he further developed his experience working as a Payer Pharmacist in charge of formulary control in a large tertiary care hospital. He then trained and qualified as a Health Economist at Glaxo Welcome working in oncology and diabetes, including the first NICE submission in 1998/9. As Head of EU Market Access at Wyeth, he led nearly 50 HTA submissions across more than 10 brands. He focused on the internationalisation of ENBREL, PREVENAR and EFEXOR, guiding them through multiple pricing and reimbursement processes. Within inflammation, he lead the reimbursement of ENBREL in RA, psoriasis, psoriatic arthritis, and ankylosing spondylitis, and is an author on several papers relating to economics in RA, including the first economic model for biologics in RA. More recently, he was Executive Director, Head of UK Market Access at Grunenthal UK covering health outcomes, market access marketing, government affairs and field-based payer interface specialising in the area of pain. Most recently he was Head of Global Market Access for Norgine Ltd.